Puma Biotechnology Sees Q4 Sales $67.000M-$70.000M vs $66.600M Est
Benzinga Newsdesk 12 months ago
NewsGuidance
Puma Biotechnology (NASDAQ:PBYI) sees Q4 sales of $67.000 million-$70.000 million vs $66.600 million analyst estimate.
Puma Biotechnology (NASDAQ:PBYI) sees Q4 sales of $67.000 million-$70.000 million vs $66.600 million analyst estimate.